Compare ETV & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest
Current Price
| Metric | ETV | INSP |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | 1333 |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.2B |
| IPO Year | 2005 | 2018 |
| Metric | ETV | INSP |
|---|---|---|
| Price | $15.20 | $77.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $94.00 |
| AVG Volume (30 Days) | 138.0K | ★ 566.4K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 179.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,050,000.00 |
| Revenue This Year | N/A | $8.02 |
| Revenue Next Year | N/A | $8.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 62.18 |
| 52 Week Low | $13.13 | $38.91 |
| 52 Week High | $15.49 | $147.03 |
| Indicator | ETV | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 52.28 | 76.53 |
| Support Level | $14.22 | $57.67 |
| Resistance Level | $15.38 | $86.00 |
| Average True Range (ATR) | 0.18 | 3.61 |
| MACD | -0.03 | 0.86 |
| Stochastic Oscillator | 55.65 | 89.12 |
Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of common stocks, designated segments of which seek to exceed the total return performance of the S&P 500 and the NASDAQ-100.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.